Martin A. Lehr
Chief Executive Officer at Context Therapeutics Inc.
Sits on 1 board. Last updated September 27, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Context Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Context Therapeutics Inc. June 24, 2026100.0%
-
Context Therapeutics Inc. June 13, 202499.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 9, 2025 | Context Therapeutics Inc. | Open-market purchase | +100,000 | $0.70 | $70,000 |
| Feb 21, 2023 | Context Therapeutics Inc. | Open-market purchase | +5,823 | $0.84 | $4,891 |
| Feb 13, 2023 | Context Therapeutics Inc. | Open-market purchase | +5,606 | $0.87 | $4,877 |
| Feb 6, 2023 | Context Therapeutics Inc. | Open-market purchase | +5,040 | $0.97 | $4,889 |
| Jan 30, 2023 | Context Therapeutics Inc. | Open-market purchase | +7,027 | $0.70 | $4,919 |
| Jan 23, 2023 | Context Therapeutics Inc. | Open-market purchase | +6,839 | $0.72 | $4,924 |
| Jan 17, 2023 | Context Therapeutics Inc. | Open-market purchase | +6,783 | $0.74 | $5,019 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.